glp 1 semaglutide Types of GLP-1 Medications for Weight Loss: Differences, Uses & Safety Novo Nordisk Drops Hims &

Nutr Res Rev, 2018

Its ideal for individuals with low energy, slow metabolism, difficulty losing fat, or anyone wanting to support active living, aging metabolism, or exercise recovery

Affordability : Cash costs and insurance coverage are important considerations

Here is a side-by-side comparison based on available trial data: Semaglutide 2.4 mg (Wegovy): 14.9% average weight loss over 68 weeks, GLP-1 receptor agonist only Tirzepatide 15 mg (Zepbound/Mounjaro): 20.9% average weight loss over 72 weeks, dual GLP-1 and GIP agonist Retatrutide 12 mg: 24.2% average weight loss over 48 weeks, triple GLP-1, GIP, and glucagon agonist What I found interesting in the data is that retatrutide appears to produce faster early weight loss than either semaglutide or tirzepatide

Research suggests that some people may regain weight after stopping Wegovy